Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could help diabetics lose weight and lower blood sugar

NCT ID NCT05110846

Disease control Sponsor: Carmot Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new daily injection called CT-868 in 103 overweight or obese adults with type 2 diabetes. Participants received either the drug or a placebo for 26 weeks. The main goal was to see if CT-868 could lower blood sugar levels (HbA1c) and help with weight loss.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CT-868 (a once-daily injection)
What this could lead to
If successful, this could point toward a new daily injection that helps control blood sugar and reduce weight in people with type 2 diabetes.
What could go wrong
This is a Phase 2 trial with only 103 participants, so results may not apply to everyone. The drug is still experimental and may not prove better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

103 people

The number who actually took part.

Started

Feb 2022

Finished

Feb 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or Females with T2DM * BMI of ≥27 kg/m2, inclusive * 18-75 years old, inclusive * Stable body weight for 3 months Exclusion Criteria: * Significant medical history * Uncontrolled diabetes * History of malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Type 2 diabetes mellitus

Contacts and locations

Locations

  • Carmot Clinical Center MX01

    Monterrey, Nuevo León, Mexico

  • Carmot Clinical Center MX02

    Monterrey, Nuevo León, Mexico

  • Carmot Clinical Center MX03

    Mexico City, Mexico

  • Carmot Clinical Center MX04

    Guadalajara, Jalisco, Mexico

  • Carmot Clinical Center MX05

    Mérida, Yucatán, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.